Ken Griffin Evolus, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$10.66 - $17.48 $188,682 - $309,396	-17,700 Reduced 48.1%	19,100 $309,000
Q2 2024 Aug 14, 2024	SELL	$10.45 - $13.76 $396,055 - $521,504	-37,900 Reduced 50.74%	36,800 $399,000
Q1 2024 May 15, 2024	BUY	$9.99 - $14.91 $542,457 - $809,613	54,300 Added 266.18%	74,700 $1.05 Million
Q4 2023 Feb 14, 2024	SELL	$7.6 - $10.53 $194,560 - $269,568	-25,600 Reduced 55.65%	20,400 $214,000
Q3 2023 Nov 14, 2023	BUY	$7.15 - $10.2 $229,515 - $327,420	32,100 Added 230.94%	46,000 $420,000
Q2 2023 Aug 14, 2023	SELL	$7.23 - $10.52 $23,136 - $33,664	-3,200 Reduced 18.71%	13,900 $101,000
Q1 2023 May 15, 2023	SELL	$7.81 - $11.05 $605,275 - $856,375	-77,500 Reduced 81.92%	17,100 $144,000
Q4 2022 Feb 14, 2023	SELL	$6.52 - $8.95 $25,428 - $34,905	-3,900 Reduced 3.96%	94,600 $710,000
Q3 2022 Nov 14, 2022	SELL	$7.76 - $13.72 $96,224 - $170,128	-12,400 Reduced 11.18%	98,500 $793,000

169

47.8M

130K

51K

Ticker EOLS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 56,094,800
Market Cap $679M
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.